Avadel Pharmaceuticals PLC Sponsored ADR Stock

$12.75

1.19% yesterday

Nasdaq, Sep 27, 10:00 pm CET

ISIN

US05337M1045

Symbol

AVDL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Avadel Pharmaceuticals PLC Sponsored ADR Stock price

$12.75

+8.50 200.00% 5Y

Nasdaq, Closing price Fri, Sep 27 2024

+0.15 1.19%

ISIN

US05337M1045

Symbol

AVDL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Market capitalization	$1.21b
Enterprise Value	$1.18b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	12.39
P/S ratio (TTM) P/S ratio	12.75
P/B ratio (TTM) P/B ratio	17.25
Revenue growth (TTM) Revenue growth	6,260.23%
Revenue (TTM) Revenue	$95.15m
EBIT (operating result TTM) EBIT	$-98.79m
Free Cash Flow (TTM) Free Cash Flow	$-112.78m
Cash position	$71.38m
EPS (TTM) EPS	$-1.15
P/E forward	negative
P/S forward	7.00
EV/Sales forward	6.81
Short interest	14.16%

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Get Started for Free Today

Avadel Pharmaceuticals PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a Avadel Pharmaceuticals PLC Sponsored ADR forecast:

11x Buy

100%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a Avadel Pharmaceuticals PLC Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Avadel Pharmaceuticals PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	95 95	6,243% 6,243% 100%
- Direct Costs	5.72 5.72	159% 159% 6%
Gross Profit	91 91	12,740% 12,740% 96%
- Selling and Administrative Expenses	176 176	80% 80% 185%
- Research and Development Expense	12 12	28% 28% 13%
EBITDA	-97 -97	16% 16% -102%
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-99 -99	16% 16% -104%
Net Profit	-106 -106	26% 26% -112%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Avadel Pharmaceuticals PLC Sponsored ADR Stock News

Positive

Seeking Alpha

●

25 days ago

Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On

Avadel shareholders have enjoyed impressive gains of approximately 77% since my last article, reflecting positive developments in the company's performance. The article provides a comprehensive review of Avadel's progress and how it is faring against Jazz Pharmaceuticals in the oxybate market. Despite its lack of a conventional pipeline, the peak sales potential of LUMRYZ in its approved indica...

Neutral

GlobeNewsWire

●

25 days ago

Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)

– Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ over twice-nightly oxybate regimens –

Neutral

GlobeNewsWire

●

about one month ago

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:

More Avadel Pharmaceuticals PLC Sponsored ADR News

Company Profile

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. It offers Bloxiverz, Vazculep, and Akovaz. The company was founded on December 1, 2015 and is headquartered in Dublin, Ireland.

Head office	Ireland
CEO	Gregory Divis
Employees	154
Founded	2015
Website	www.avadel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now